A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation
NCT06006793
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Advanced Solid Tumor
Interventions
DRUG:
SY-5933
Sponsor
Shouyao Holdings (Beijing) Co. LTD